Immunology for
a Better Future
Learn More
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Advancing Therapeutic
Solutions
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
Focused on Improving
Lives
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Key Highlights
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will present at the...
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
OCALA, Fla., March 26, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at...
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced the publication of new data analysis from a long-term...